NO2887953T3 - - Google Patents

Info

Publication number
NO2887953T3
NO2887953T3 NO13838871A NO13838871A NO2887953T3 NO 2887953 T3 NO2887953 T3 NO 2887953T3 NO 13838871 A NO13838871 A NO 13838871A NO 13838871 A NO13838871 A NO 13838871A NO 2887953 T3 NO2887953 T3 NO 2887953T3
Authority
NO
Norway
Application number
NO13838871A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2887953T3 publication Critical patent/NO2887953T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO13838871A 2012-08-23 2013-08-22 NO2887953T3 (cg-RX-API-DMAC10.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2452MU2012 2012-08-23
PCT/IN2013/000511 WO2014045296A2 (en) 2012-08-23 2013-08-22 Improved daptomycin injectable formulation

Publications (1)

Publication Number Publication Date
NO2887953T3 true NO2887953T3 (cg-RX-API-DMAC10.html) 2018-03-10

Family

ID=54187094

Family Applications (1)

Application Number Title Priority Date Filing Date
NO13838871A NO2887953T3 (cg-RX-API-DMAC10.html) 2012-08-23 2013-08-22

Country Status (12)

Country Link
US (1) US20150216928A1 (cg-RX-API-DMAC10.html)
EP (2) EP3287138A1 (cg-RX-API-DMAC10.html)
JP (1) JP2015526463A (cg-RX-API-DMAC10.html)
AU (2) AU2013319737B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015003198A2 (cg-RX-API-DMAC10.html)
CA (1) CA2881121A1 (cg-RX-API-DMAC10.html)
DK (1) DK2887953T3 (cg-RX-API-DMAC10.html)
ES (1) ES2655215T3 (cg-RX-API-DMAC10.html)
NO (1) NO2887953T3 (cg-RX-API-DMAC10.html)
PT (1) PT2887953T (cg-RX-API-DMAC10.html)
SI (1) SI2887953T1 (cg-RX-API-DMAC10.html)
WO (1) WO2014045296A2 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4066849T3 (pl) * 2012-09-11 2025-06-16 Hospira Australia Pty Ltd Preparaty daptomycyny i ich zastosowania
WO2018073269A1 (en) 2016-10-21 2018-04-26 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
US11759497B2 (en) 2017-08-31 2023-09-19 Xellia Pharmaceuticals Aps Daptomycin formulations
EP4110303A1 (en) 2020-02-28 2023-01-04 Xellia Pharmaceuticals ApS Daptomycin formulation
EP4117625A1 (en) 2020-03-12 2023-01-18 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
CN112684043A (zh) * 2020-12-16 2021-04-20 南京健友生化制药股份有限公司 一种达托霉素有关物质的检测方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
FR2657526B1 (fr) * 1990-01-31 1994-10-28 Lvmh Rech Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues.
CN1069320C (zh) * 1995-10-17 2001-08-08 昭和电工株式会社 高纯度生育酚磷酸酯,其生产方法和含有该化合物的化妆品
JP4088597B2 (ja) * 2004-01-06 2008-05-21 樹男 飯田 内服および注射用組成物とその製法
CA2564180A1 (en) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical preparation containing bacterial cell wall skeleton component
US9168216B2 (en) * 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
CN102625697A (zh) * 2009-09-01 2012-08-01 西北大学 使用经寡核苷酸修饰的纳米颗粒作为载体来递送治疗剂
US8431539B2 (en) * 2009-09-17 2013-04-30 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
CA2781666C (en) * 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
WO2011094814A1 (en) * 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
CA2752784A1 (en) * 2010-09-21 2012-03-21 Xellia Pharmaceuticals Aps Daptomycin formulation

Also Published As

Publication number Publication date
PT2887953T (pt) 2018-01-10
AU2013319737A1 (en) 2015-02-05
EP2887953A4 (en) 2016-05-25
EP2887953B1 (en) 2017-10-11
EP3287138A1 (en) 2018-02-28
ES2655215T3 (es) 2018-02-19
JP2015526463A (ja) 2015-09-10
WO2014045296A2 (en) 2014-03-27
DK2887953T3 (en) 2018-01-15
US20150216928A1 (en) 2015-08-06
CA2881121A1 (en) 2014-03-27
WO2014045296A3 (en) 2014-10-23
EP2887953A2 (en) 2015-07-01
AU2018204334A1 (en) 2018-07-05
BR112015003198A2 (pt) 2017-10-10
SI2887953T1 (en) 2018-02-28
AU2013319737B2 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
BR112014017635A2 (cg-RX-API-DMAC10.html)
BR112014017614A2 (cg-RX-API-DMAC10.html)
BR112014018331A2 (cg-RX-API-DMAC10.html)
BR112014017625A2 (cg-RX-API-DMAC10.html)
BR112014017659A2 (cg-RX-API-DMAC10.html)
BR112014017607A2 (cg-RX-API-DMAC10.html)
BR112014017592A2 (cg-RX-API-DMAC10.html)
BR112014017646A2 (cg-RX-API-DMAC10.html)
BR112014017638A2 (cg-RX-API-DMAC10.html)
AR092201A1 (cg-RX-API-DMAC10.html)
BR112013027865A2 (cg-RX-API-DMAC10.html)
BR112014026869B8 (cg-RX-API-DMAC10.html)
BR112014017609A2 (cg-RX-API-DMAC10.html)
BR112014017644A2 (cg-RX-API-DMAC10.html)
BR112014019843A2 (cg-RX-API-DMAC10.html)
BR112014017634A2 (cg-RX-API-DMAC10.html)
BR112014017588A2 (cg-RX-API-DMAC10.html)
BR112014017647A2 (cg-RX-API-DMAC10.html)
BR112014013184A8 (cg-RX-API-DMAC10.html)
BR112014017627A2 (cg-RX-API-DMAC10.html)
BR112014017630A2 (cg-RX-API-DMAC10.html)
BR112014017641A2 (cg-RX-API-DMAC10.html)
BR112014017621A2 (cg-RX-API-DMAC10.html)
BR112014017631A2 (cg-RX-API-DMAC10.html)
BR112014020219A2 (cg-RX-API-DMAC10.html)